CY1118074T1 - Ανθελονοσιακοι παραγοντες - Google Patents

Ανθελονοσιακοι παραγοντες

Info

Publication number
CY1118074T1
CY1118074T1 CY20161100998T CY161100998T CY1118074T1 CY 1118074 T1 CY1118074 T1 CY 1118074T1 CY 20161100998 T CY20161100998 T CY 20161100998T CY 161100998 T CY161100998 T CY 161100998T CY 1118074 T1 CY1118074 T1 CY 1118074T1
Authority
CY
Cyprus
Prior art keywords
antelonossian
factors
relates
present
malaria
Prior art date
Application number
CY20161100998T
Other languages
English (en)
Inventor
Yassir Younis
Kelly Chibale
Michael John Witty
David Waterson
Original Assignee
University Of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Cape Town filed Critical University Of Cape Town
Publication of CY1118074T1 publication Critical patent/CY1118074T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στη χρήση παραγώγων αμινοπυραζίνης στη βιομηχανική κατασκευή ενός φαρμάκου για πρόληψη ή θεραπεία ελονοσίας. Ειδικώς, η παρούσα εφεύρεση σχετίζεται προς παράγωγα αμινοπυραζίνης χρήσιμα για την παρασκευή μιας φαρμακευτικής συνταγοποίησης για την αναστολή πολλαπλασιασμού του παρασίτου της ελονοσίας.
CY20161100998T 2012-02-17 2016-10-10 Ανθελονοσιακοι παραγοντες CY1118074T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600324P 2012-02-17 2012-02-17
PCT/IB2013/051235 WO2013121387A1 (en) 2012-02-17 2013-02-15 Anti -malarial agents

Publications (1)

Publication Number Publication Date
CY1118074T1 true CY1118074T1 (el) 2017-06-28

Family

ID=48014134

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100998T CY1118074T1 (el) 2012-02-17 2016-10-10 Ανθελονοσιακοι παραγοντες

Country Status (21)

Country Link
US (1) US9266842B2 (el)
EP (1) EP2814820B1 (el)
JP (1) JP6226889B2 (el)
CN (1) CN104136426B (el)
BR (1) BR112014020212B1 (el)
CA (1) CA2864483A1 (el)
CY (1) CY1118074T1 (el)
DK (1) DK2814820T3 (el)
ES (1) ES2589283T3 (el)
HK (1) HK1202859A1 (el)
HR (1) HRP20161237T1 (el)
HU (1) HUE029876T2 (el)
IN (1) IN2014MN01622A (el)
LT (1) LT2814820T (el)
ME (1) ME02535B (el)
PL (1) PL2814820T3 (el)
PT (1) PT2814820T (el)
SI (1) SI2814820T1 (el)
SM (1) SMT201600441B (el)
WO (1) WO2013121387A1 (el)
ZA (1) ZA201406786B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013121387A1 (en) * 2012-02-17 2013-08-22 University Of Cape Town Anti -malarial agents
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017067881A1 (en) * 2015-10-19 2017-04-27 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds for use in the treatment of parasitic protozoal infections
WO2019145360A1 (en) * 2018-01-24 2019-08-01 Glaxosmithkline Intellectual Property Development Limited Novel compounds for the treatment of parasitic infections
CN112142715A (zh) * 2020-10-10 2020-12-29 鲁南制药集团股份有限公司 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途
AU2022395361A1 (en) * 2021-11-23 2024-05-30 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds useful in the treatment of parasitic protozoal infection
WO2024033280A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria
WO2024033281A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furo pyrimidine derivates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2277865E (pt) * 2003-12-03 2015-02-05 Ym Biosciences Australia Pty Heterociclos de azoto de anel de 6 membros fenil substituídos como inibidores de polimerização de microtúbulos
JP2009541268A (ja) * 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
RS54339B1 (en) 2010-01-18 2016-02-29 Mmv Medicines For Malaria Venture NEW ANTIMALARIAN AGENTS
WO2011143423A2 (en) * 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR20140014205A (ko) * 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
WO2013121387A1 (en) * 2012-02-17 2013-08-22 University Of Cape Town Anti -malarial agents

Also Published As

Publication number Publication date
PL2814820T3 (pl) 2017-01-31
IN2014MN01622A (el) 2015-05-15
DK2814820T3 (en) 2016-10-03
LT2814820T (lt) 2016-10-25
HUE029876T2 (en) 2017-04-28
EP2814820B1 (en) 2016-07-20
PT2814820T (pt) 2016-10-25
EP2814820A1 (en) 2014-12-24
US20150031682A1 (en) 2015-01-29
ES2589283T3 (es) 2016-11-11
ME02535B (me) 2017-02-20
SI2814820T1 (sl) 2016-10-28
HRP20161237T1 (hr) 2016-11-04
CN104136426A (zh) 2014-11-05
HK1202859A1 (en) 2015-10-09
CN104136426B (zh) 2017-10-03
JP6226889B2 (ja) 2017-11-08
US9266842B2 (en) 2016-02-23
WO2013121387A1 (en) 2013-08-22
CA2864483A1 (en) 2013-08-22
JP2015507004A (ja) 2015-03-05
ZA201406786B (en) 2015-06-24
BR112014020212B1 (pt) 2021-11-23
BR112014020212A8 (pt) 2018-01-23
SMT201600441B (it) 2017-01-10

Similar Documents

Publication Publication Date Title
CY1118074T1 (el) Ανθελονοσιακοι παραγοντες
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121793T1 (el) Εκλεκτικοι αναστολεις pi3k δελτα
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
ECSP19078196A (es) Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
TN2015000278A1 (en) Autotaxin inhibitors
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
MX366899B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
GB201209613D0 (en) New compounds
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
IN2014DN10670A (el)
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон